GLP-1 Medication Comparison: Ozempic vs Wegovy vs Mounjaro vs Zepbound
For diabetes: Mounjaro (most effective) > Ozempic > older options. For weight management: Zepbound (~21% loss) > Wegovy (~15%) > Saxenda (~8%). Insurance coverage often dictates choice. Side effect profiles are similar within drug class. Cost varies widely; cash-pay manufacturer programs are an option.
The GLP-1 medication landscape can be confusing — multiple molecules, brand names that overlap by indication, similar dosing schedules. Here is the practical side-by-side comparison.
The molecules
There are essentially three molecules currently approved in the U.S.:
- Semaglutide (sold as Ozempic, Wegovy, Rybelsus)
- Tirzepatide (sold as Mounjaro, Zepbound)
- Liraglutide (sold as Victoza, Saxenda)
A few others (dulaglutide, exenatide) are less commonly used for weight loss.
Quick comparison table
| Wegovy | Zepbound | Ozempic | Mounjaro | Saxenda | Rybelsus | |
|---|---|---|---|---|---|---|
| Molecule | Semaglutide | Tirzepatide | Semaglutide | Tirzepatide | Liraglutide | Semaglutide |
| FDA indication | Weight | Weight | Diabetes | Diabetes | Weight | Diabetes |
| Frequency | Weekly inj | Weekly inj | Weekly inj | Weekly inj | Daily inj | Daily oral |
| Max dose | 2.4 mg | 15 mg | 2.0 mg | 15 mg | 3.0 mg | 14 mg |
| Avg weight loss | ~15% | ~21% | ~10% | ~18% | ~8% | ~5–8% |
| List price/mo | ~$1,350 | ~$1,060 | ~$1,000 | ~$1,070 | ~$1,400 | ~$900 |
| Manufacturer | Novo Nordisk | Eli Lilly | Novo Nordisk | Eli Lilly | Novo Nordisk | Novo Nordisk |
Decision framework
"I want maximum weight loss"
Best choice: Zepbound (or Mounjaro if diabetic)
- Average ~21% weight loss at maximum dose
- More patients lose 25%+ of body weight than on semaglutide
- Side effect profile similar to semaglutide
"I want the best-studied option"
Best choice: Wegovy (or Ozempic if diabetic)
- Largest body of clinical data
- SELECT trial shows cardiovascular benefit independent of weight
- Available longer; more real-world experience
"I have type 2 diabetes"
Best choice: Mounjaro > Ozempic
- Mounjaro typically produces stronger HbA1c reduction
- Both produce significant weight loss
- Coverage usually better for diabetes-indicated drugs
"I have severe side effects on stronger options"
Best choice: Saxenda > Rybelsus
- Saxenda's gentler appetite suppression may be more tolerable
- Rybelsus has milder GI effects (oral, lower absorption)
- Less effective for weight loss but easier to tolerate
"I can't or won't inject"
Best choice: Rybelsus
- Only oral GLP-1 currently available
- Strict morning timing required (fasted, 4 oz water, 30 min before food)
- Less effective than injectable options
"Insurance only covers one"
Take it. Don't fight your insurance for a marginal upgrade. Whichever they cover, it works — the core mechanisms are the same.
"I have cardiovascular disease"
Best choice: Wegovy
- Specifically approved for cardiovascular event reduction in CVD patients with obesity (post-SELECT)
- Strongest data for non-diabetic CV benefit
Side effect comparison
Generally similar across the class:
| Side effect | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Nausea | Common | Common | Common |
| Diarrhea | Common | More common | Common |
| Constipation | Common | Common | Common |
| Sulfur burps | Some | More common | Some |
| Vivid dreams | Some | Some | Less common |
| Injection reactions | Mild | Mild | More common |
| Pancreatitis risk | Rare | Rare | Rare |
| Thyroid C-cell warning | Yes | Yes | Yes |
| Gallbladder issues | Some | Some | Less common |
The profile is more similar than different.
Cost comparison (for self-pay)
Approximate monthly out-of-pocket through manufacturer programs:
- Zepbound (LillyDirect, vials): ~$400–500
- Wegovy (NovoCare): ~$500–650
- Mounjaro: ~$500–650 (Lilly programs)
- Ozempic: ~$500–650
- Saxenda: ~$700–1,000
- Rybelsus: ~$900–1,000
Compounded options (with safety caveats) can be lower.
What about new agents?
In development:
- Retatrutide (triple agonist — GLP-1 + GIP + glucagon): showing 24%+ weight loss in trials
- CagriSema (semaglutide + cagrilintide combination): higher weight loss than semaglutide alone
- Orforglipron (oral non-peptide GLP-1): may rival injectable effectiveness in pill form
- Survodutide, mazdutide (other dual/triple agonists)
Most are 1–3+ years from FDA approval.
Switching between medications
Patients commonly switch:
- Insurance coverage changes
- Side effects don't resolve on one
- Plateau on one — try another
- Supply issues
- Cost changes
The transition is usually smooth. Your prescriber will start you at an equivalent or starter dose on the new drug.
What's the same across all of them
Regardless of which GLP-1 you're on:
- The protein floor is the same (0.7–1.0 g/lb goal weight)
- Resistance training requirement is the same
- Side effect management is similar
- Maintenance and rebound considerations apply
- The off-ramp protocol is similar
The drug differences matter for absolute weight loss; the lifestyle protocol matters for what you keep.
Bottom line
For maximum weight loss in non-diabetics: Zepbound. For diabetes: Mounjaro. For most-studied with cardiovascular benefit: Wegovy. For oral or maximum tolerability: Rybelsus or Saxenda. Insurance coverage is often the deciding factor in practice. Whatever you take, the protein and lifting protocol determines what you keep.